title: Profibrinolytic activities of chemically modified heparins with very low anticoagulant activities.
abstract: Many evidences indicate that heparin is an activator of fibrinolysis, but the most important side effect of heparin is bleeding which is a problem particularly in the high risk patient. Here we describe how chemical modifications, associated with separation techniques, can sharply reduce the anticoagulant activities of a heparin while its ability to stimulate fibrinolysis is retained.
authors.affiliation: Crinos Biological Laboratories, Como, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Porta
authors.forename: R
authors.initials: R
authors.lastname: Pescador
authors.forename: R
authors.initials: R
authors.lastname: Niada
authors.forename: G
authors.initials: G
authors.lastname: Diamantini
authors.forename: G F
authors.initials: GF
authors.lastname: Fedeli
authors.forename: M
authors.initials: M
authors.lastname: Mantovani
authors.forename: G
authors.initials: G
authors.lastname: Prino
mesh_terms: D000818:Animals; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006493:Heparin / Q000302:isolation & purification / Q000494:pharmacology*; D066298:In Vitro Techniques; D008297:Male; D008970:Molecular Weight; D010084:Oxidation-Reduction; D011817:Rabbits; D051381:Rats; D012756:Sheep; D013552:Swine; D014574:Uronic Acids / Q000032:analysis
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014574:Uronic Acids; D006493:Heparin